Scenario Planning for the $300B Patent Cliff: A Finance Leader’s Playbook for 2026-2030

Between 2025 and 2030, more than $300 billion in prescription drug revenues will lose patent exclusivity. That is roughly one-sixth of the entire industry’s annual revenue. Nearly 200 drugs are on the expiry list, with 70 of them generating over $1 billion in sales annually. The previous cliff, in 2016, wiped out about $100 billion in brand-name sales. This one is three times that size.

None of this is a secret. Every expiry date was filed with the USPTO, every revenue figure is reported on quarterly earnings calls, and there is a plethora of public-domain information citing it. This cliff isn’t sneaking up on anyone. It has announced itself years in advance, drug by drug, market by market.

The problem companies are facing with it is that many pharma finance teams are still running a single, baseline forecast. Doing this assumes the upcoming patent cliff is a revenue event (a single, foreseeable shock to be absorbed). Smart finance teams know better and treat it as a possibility matrix with four plausible futures, modeled simultaneously, each with decision triggers.

Eight of the 13 largest pharmaceutical firms, which represent ~55% of global market value, could see 30% or more of their revenue disappear. This could result in per-company losses ranging from $6 billion to $38 billion.

The marquee victims are well known:

• Keytruda (pembrolizumab, Merck), the best-selling drug on the planet, is expected to peak around $32 billion in sales in 2026 before facing biosimilar erosion starting in 2028.
• Bristol Myers Squibb has a potential revenue growth gap of approximately $38 billion as Eliquis and Opdivo together approach loss of exclusivity.
• Pfizer’s Xeljanz expires in 2026, Ibrance in 2027, and Enbrel in 2028.

When revenue drops hit, it is relentless. Pfizer’s Lipitor plummeted from $2.6 billion in Q3 2011 to $749 million in Q3 2012, a devastating 71% collapse in just a year after patent expiry. Humira tells a similar story: the moment biosimilar Amjevita entered with a 55% price discount, Humira’s revenue crashed from $21.2 billion in 2022 to $9 billion in 2024.

Historical precedents on small-molecule erosion is limited. Prices can drop by one-third in the first year and by more than 80% within eight years of expiration.

The Inflation Reduction Act (IRA) Medicare drug price negotiation program is compressing margins on branded drugs that still have years of exclusivity left.

Starting in 2026, the first 10 Part D drugs selected for negotiation received price cuts of 38%–79% off list price. CMS obtained greater reductions than the mandatory minimums in all ten cases, a result almost no one had predicted. According to the Brookings Institution analysis, the second round of negotiations (November 2025) produced an average MFP that was 44% below pre-IRA net prices. The program will expand on a schedule with 15 additional drugs for 2027 and 2028, and then 20 per year from 2029 forward.

In addition to the visible cut, there is the hidden commercial spillover. A majority of payers surveyed expect competitors of negotiated drugs to match or beat the MFP. Formulary demotion and step-therapy (patients must try lower-cost, effective drugs before more expensive medications) requirements are the enforcement mechanisms. Either price down or lose preferred status.

This is the double-threat scenario that most pharma finance models handle incorrectly by running Medicare and commercial revenue models independently, as if the two markets don’t talk to each other. But they do.

One of the most persistent fantasy scenarios in pharma finance modeling is the “volume offset”. This is the idea that lower IRA prices will drive enough additional utilization to recoup the revenue. In general, it won’t, for most drugs.

The price elasticity of demand (PED) for pharmaceuticals typically ranges from –0.10 to –0.20. This is supported by the RAND Health Insurance Experiment, which estimated the elasticity of medical spending at –0.2, and confirmed by a 2018 National Library of Medicine study that found a PED of –0.16 across drug categories. Applying the CBO’s projected 50% average price reduction, you can expect roughly an 8% volume increase. This would take a hypothetical drug from $50M to $54M a year, but if the drug has an annual run rate of a $100M base that leaves a net loss of $46M.

A financial model should include at least these four scenarios that cascade based on triggers.

Core assumptions: M&A will close the pipeline gap; IRA expands but remains within current Congressional authorization; biosimilar erosion follows historical curves (2–3 year ramp to peak penetration).

Revenue replacement outlook: Manageable, but not comfortable. The M&A deals signed in 2025 and 2026 won’t affect 2026 performance, they’ll affect 2030 and beyond. Most acquisitions operate on a three-to-five-year lag before influencing company performance. In a controlled burn scenario, those acquisitions will land roughly on schedule with the drop in revenue. The growth gap will shrink but may not close fully.

What to look for: Pipeline milestone hits. Integration velocity. Whether reformulation programs like Merck’s Keytruda Qlex, projected at $7 billion in sales by early 2032, reach the market on schedule.

Decision trigger: If two or more major pipeline acquisitions miss their Phase 3 milestone dates by more than 12 months, the Controlled Burn scenario graduates into Scenario B.

Core assumptions: Deals close at the 2025 pace, but pipelines don’t deliver on schedule. Clinical risk, regulatory delays, or integration failures push commercial contributions out 2–3 years beyond acquisition projections.

Revenue replacement outlook: Cash deployed but revenue isn’t there. This is the most dangerous financial scenario for the balance sheet because capital has been spent and the top line hasn’t moved. Since 2018, more than 70% of new molecular entity revenues have come from externally sourced products (M&A). A miss in the external pipeline is a misfire in the only pipeline most companies have.

Model requirement: Probability-weighted NPV for each pipeline asset, with scenario-specific clinical failure rates by development stage. At average drug development costs of approximately $2.2 billion per asset, a portfolio of five late-stage acquisitions carries $11 billion in at-risk capital before any revenue contribution.

Decision trigger: Watch deal premium levels. When acquisition multiples spike above 12x forward revenue for pre-commercial assets, the market is pricing in certainty that the clinical record doesn’t support.

Core assumptions: Congress expands the negotiation program scope faster than the current schedule; commercial market repricing cascades materially beyond the Medicare segment; the “pill penalty” fix (aligning small-molecule and biologic negotiation timelines) passes, reshaping pipeline investment economics.

Revenue replacement outlook: Margin compression driven by IRA negotiations hits non-expiring drugs at the same time as the loss-of-exclusivity (LOE) event. For example, a product like Eliquis undergoes both loss of exclusivity and competitive commercial repricing in the same 18-month window. The financial model that treats those as separate line items will be wrong on both revenue and gross margin.

The commercial spillover mechanism: Once CMS negotiates an MFP, payers use it as an anchor in commercial negotiations. This may result in branded drugs being downgraded to a non-preferred tier, as payers will use this leverage to extract concessions equivalent to those offered by generics. Additionally, the IRA’s inflation rebate penalties are structurally tied to list price increases rather than net prices, creating a layered margin problem that most models don’t entirely capture.

Model requirement: A drug-by-drug commercial repricing sensitivity analysis that stress-tests what happens if 40% of commercial book prices are down by 20–30% in the same window as the LOE event.

Decision trigger: Follow Part B drug inclusion into CMA negotiation rounds starting in 2028. If CMS moves faster than its stated timeline on biologics and physician-administered drugs, Scenario C becomes real.

Core assumptions: Biosimilar entry is faster and deeper than the Humira precedent where payer contracts accelerate adoption timelines from 3 years to 18 months; pricing undercuts reference products by 60–70%, rather than the 50–55% seen with adalimumab biosimilars.

Revenue replacement outlook: Catastrophic for companies with a biologic-heavy LOE portfolio. For example, Amgen’s Amjevita launched at 55% off Humira’s list price and drove Humira’s revenue from $21.2B to $9B in two years. The biosimilars in 2028–2029 won’t follow a slow hospital-contracting curve. They will go directly through group purchasing organization and payer formularies at 60% off. Why? Because they can.

The oncology-specific wrinkle: PD-1 therapy biosimilars move through hospital formularies, group purchasing contracts, and oncology network negotiations, not retail pharmacy switches. The Humira retail precedent underestimates how fast institutional contracting can flip.

Model requirement: Multiple biosimilar penetration curves for small-molecule, biologic, and oncology biologic products. These are three structurally different erosion dynamics.

Decision trigger: Watch biosimilar pipeline filings at the FDA for Keytruda and Opdivo in 2026–2027. Abbreviated New Drug Application) / Biologics License Application filing volume is the leading indicator of how many competitors are betting on fast penetration.

A pharma finance function that can navigate 2026–2030 without a board-level panic has six things in place before the first major LOE event hits:

1. Four, driver-based scenarios. Not four versions of a spreadsheet, but a single model that splits at key assumption nodes. Product LOE date, erosion rate, competitive entry speed, IRA round inclusion, and M&A milestone hit rate should each be drivers that update the full P&L in real time.
2. Product-level revenue models with LOE dates and product-type-specific erosion parameters. Not one erosion assumption but one per product category: small-molecule, biologic, oncology biologic.
3. An IRA tracker that integrates into the revenue forecast. Commercial market spillover sensitivity should be modeled at the therapeutic-area level, not just the Medicare revenue line. The GAO’s implementation report on the IRA negotiation program and HHS’s ASPE research series are the primary public sources for tracking program expansion timelines and drug selection criteria.
4. M&A pipeline modeled as probability-weighted NPV scenarios. Every acquired asset should carry an explicit probability of commercial success by year, based on its current clinical stage and historical success rates in that therapeutic area.
5. A rolling monthly re-forecast. Not an annual budget with quarterly check-ins but a rolling forecast that updates as LOE events, biosimilar filings, and IRA selection rounds hit.
6. Decision triggers defined in advance. Each scenario should have pre-committed triggers (observable market events) that shift the operating plan from one scenario to another. The worst time to decide which scenario you’re in is after the revenue has already moved.

The patent cliff is not arriving. It is here. The finance leaders who treat it as a single event to survive will be reactive. The ones who treat it as four parallel futures to navigate simultaneously will have an answer for the board before the board asks the question.